Drug Profile
Research programme: spinal muscular atrophy therapeutics - Lexicon Pharmaceuticals
Alternative Names: SMN protein activators - LexiconLatest Information Update: 25 Nov 2014
Price :
$50
*
At a glance
- Originator Lexicon Genetics
- Developer Lexicon Pharmaceuticals
- Class
- Mechanism of Action Survival of motor neuron 1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Spinal muscular atrophy
Most Recent Events
- 27 Nov 2008 No development reported - Preclinical for Spinal muscular atrophy in USA (unspecified route)
- 27 Apr 2007 Lexicon Genetics is now called Lexicon Pharmaceuticals
- 13 Oct 2006 Lexicon has been awarded an additional grant from the US Army and Medical Research and Material Command for the development of drugs to prevent or treat Spinal muscular atrophy